Diabetic Neuropathy Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy), By Drug Class (Non-Steroidal Anti-Inflammatory Drugs, Opioids, Anti-Depressants, Anti-Seizure, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and MEA), and Forecast to 2030.

Diabetic Neuropathy Treatment Market size was valued at US$ 4,183.7 million in 2023 and is projected to reach US$ 6,249.3 million by 2030 at a CAGR of 5.9% from 2024 to 2030. Diabetic neuropathy arises from prolonged, uncontrolled high blood sugar levels, predominantly associated with clinical diabetic conditions. Elevated glucose levels can inflict damage on nerves throughout the body, primarily affecting those in the legs and feet. Symptoms range from pain and numbness in the extremities to complications in various bodily systems such as digestion, urinary function, and cardiovascular health. With the World Health Organization projecting a significant increase in diabetes cases, reaching 438 million by 2030, the market for diabetic neuropathy treatment is expected to expand. Factors driving this growth include heightened awareness of diabetes management, the introduction of new treatment options, and the demand for innovative drug delivery methods. Additionally, factors like the ageing population, lifestyle changes, and ongoing research contribute to market expansion. However, challenges such as high product costs and alternative treatment availability hinder growth prospects.

Recent Developments of the Market:

• In December 2023, Vertex Pharmaceuticals received approval from the U.S. FDA for CRISPR-based gene editing therapy to emphasize the promotion and development of non-opioid pain management drugs.
• In January 2023, NeuroMetrix commercially launched its new DPNCheck 2.0 point-of-care device for detecting peripheral neuropathy. The new quick, accurate, quantitative test uses nerve conduction technology to detect peripheral neuropathy, the systemic degeneration of peripheral nerves.
• In January 2023, Neuralace Medical Inc., a medical technology company announced the enrolment of the first patients for its Axon Therapy and Painful Diabetic Neuropathy (AT-PDN) study with a target of around 80 patients. The study was estimated to be conducted at five clinical sites and led by Dr. Lora Brown at TruWell Health, Florida.